Our research results demonstrated that by connecting anti-PD-L1 nanobodies to the surface of liposomes carrying cGAMP, cGAMP could be specifically targeted and delivered to hepatoma cells expressing PD-L1. This evidence concerns the gene CD274 and hepatocellular carcinoma.